TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32298144

Group type: EXPERIMENTAL
Intervention: Patients with large hrQoL improvement (≥18 points increase in Atrial Fibrillation Effect on Quality-of-Life score)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Patients without large hrQoL improvement
Number of subjects: 636
Study: 32298288

Group type: EXPERIMENTAL
Intervention: Combined neoadjuvant chemotherapy with bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32298429

Group type: EXPERIMENTAL
Intervention: Posttreatment bone marrow biopsy (BMB) histology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postinduction BMB histology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone marrow evaluation
Number of subjects: 0
Study: 32298699

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone treatment
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Sputum microbiota
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Oral microbiota
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Sputum and oral microbiota
Number of subjects: 66
Study: 32298906

Group type: EXPERIMENTAL
Intervention: High RT dose to the left hippocampus
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: RT dose to the left hippocampus, left temporal lobe, left frontal lobe, and total frontal lobe
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: RT dose to the thalamus and the left frontal lobe
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: RT dose to the brain and thalamus
Number of subjects: 78
Study: 32298961

Group type: EXPERIMENTAL
Intervention: Pictograph illustrating uncertainty for local recurrence risks with textual explanation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Verbal labels for prevalence and severity of side-effects
Number of subjects: 100
Study: 32299118

Group type: EXPERIMENTAL
Intervention: INVADE intervention program
Number of subjects: 10663

Group type: COMPARATOR
Intervention: Usual primary care treatment in Dachau
Number of subjects: 10663
Study: 32299390

Group type: EXPERIMENTAL
Intervention: IBD Disk
Number of subjects: 400

Group type: COMPARATOR
Intervention: IBD-DI
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: PGA (Physician Global Assessment)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: PtGA (Patient Global Assessment)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: IBD Disk psychometric criteria
Number of subjects: 400
Study: 32299401

Group type: EXPERIMENTAL
Intervention: Transition Readiness and Appropriateness Measure (TRAM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transition Related Outcome Measure (TROM)
Number of subjects: 0
Study: 32299420

Group type: EXPERIMENTAL
Intervention: Family Talk Intervention (FTI)
Number of subjects: 34
Study: 32299778

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 402
Study: 32299817

Group type: EXPERIMENTAL
Intervention: CIVO microinjected drugs
Number of subjects: 13
Study: 32299865

Group type: EXPERIMENTAL
Intervention: Ozone exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32300321

Group type: EXPERIMENTAL
Intervention: 1 week of multiple-game exergaming (including single leg exercises, weight shifting, balancing, and standing up)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 week of conventional balance training
Number of subjects: 0
Study: 32300475

Group type: EXPERIMENTAL
Intervention: HiBalance
Number of subjects: 13

Group type: COMPARATOR
Intervention: HiCommunication
Number of subjects: 13
Study: 32300671

Group type: EXPERIMENTAL
Intervention: Intranasal Ketamine
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 140
Study: 32300702

Group type: EXPERIMENTAL
Intervention: Co-created intervention developed through service-learning methodology
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 60
Study: 32300966

Group type: EXPERIMENTAL
Intervention: Propofol induction dose
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Higher propofol doses
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Excess propofol dose
Number of subjects: 541
Study: 32301062

Group type: EXPERIMENTAL
Intervention: 0.2 ml/kg dose of IGIM
Number of subjects: 28
Study: 32301063

Group type: EXPERIMENTAL
Intervention: Dienogest 2 mg/day
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: Other hormonal medications
Number of subjects: 25000

Group type: COMPARATOR
Intervention: Dienogest 2 mg/day and other hormonal medications
Number of subjects: 25000
Study: 32301258

Group type: EXPERIMENTAL
Intervention: tesidolumab + IVIg
Number of subjects: 8

Group type: COMPARATOR
Intervention: tesidolumab alone
Number of subjects: 8
Study: 32301783

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32301981

Group type: EXPERIMENTAL
Intervention: Weight Loss (WL)
Number of subjects: 34
Study: 32303155

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32303189

Group type: EXPERIMENTAL
Intervention: Anterior Active Rhinomanometry (AAR)
Number of subjects: 0
Study: 32303379

Group type: EXPERIMENTAL
Intervention: QoR-15F scale administered pre-operation and on Postoperative day 1
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: QoR-15F scale
Number of subjects: 150
Study: 32303514

Group type: EXPERIMENTAL
Intervention: Inappropriate reasons for ED presentation (no urgent treatment required)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Symptoms as a reason for ED presentation
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: General fear or anxiety as a reason for ED presentation
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Prior medical advice as a reason for ED presentation
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: History of congestive heart failure
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Symptom-related concerns for ED presentation
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Preference for alternatives to ED care
Number of subjects: 356
Study: 32303612

Group type: EXPERIMENTAL
Intervention: CRP treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: High serum CRP levels
Number of subjects: 0
Study: 32303619

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 57
Study: 32303743

Group type: COMPARATOR
Intervention: Eucaloric diet (CON; n = 11)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-fat overfeeding diet (HFD; n = 9; 50% excess energy as fat)
Number of subjects: 20
Study: 32303913

Group type: EXPERIMENTAL
Intervention: Combined retinal electromagnetic stimulation and subtenon platelet-rich plasma (group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subtenon platelet-rich plasma only (group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Natural course (control group 3)
Number of subjects: 60
Study: 32303994

Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) as first-line biologic agent
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) as second-line biologic agent
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) as at least third-line biologic agent
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) in PsA as first-line biologic agent
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) in PsA as second-line biologic agent
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) in PsA as at least third-line biologic agent
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) in AS as first-line biologic agent
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) in AS as second-line biologic agent
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) in AS as at least third-line biologic agent
Number of subjects: 1454
Study: 32304462

Group type: EXPERIMENTAL
Intervention: Cocaine-positive group
Number of subjects: 328

Group type: COMPARATOR
Intervention: Cocaine-negative group
Number of subjects: 328
Study: 32304510

Group type: EXPERIMENTAL
Intervention: Leg extensor (LE) maximal muscle power measured in a Nottingham Power Rig
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Knee extensor (KE) peak isometric strength measured with a handheld dynamometer
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 40-m walk test
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 30-second chair-stand test
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 9-step stair climb test
Number of subjects: 40
Study: 32304640

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 0
Study: 32304847

Group type: EXPERIMENTAL
Intervention: Theta/Beta Neurofeedback (NFB)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Methylphenidate (MPH)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Physical Activity (PA)
Number of subjects: 67
Study: 32304877

Group type: EXPERIMENTAL
Intervention: Biologics (n=557); 51% anti-immunoglobulin E, 48% anti-IL-5/IL-5Rα; 76% of initiations from May 2018 were anti-IL-5/IL-5Rα
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Maintenance systemic corticosteroids (mSCS); median prednisone-equivalent daily dose of 10 mg
Number of subjects: 796

Group type: COMPARATOR
Intervention: Patients of hospital clinics, sites with fewer nonphysician staff, and with a recorded concurrent chronic obstructive pulmonary disease diagnosis
Number of subjects: 796
Study: 32305010

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 400 mg every 6 weeks (Q6W)
Number of subjects: 2993

Group type: COMPARATOR
Intervention: Pembrolizumab 200 mg every 3 weeks (Q3W)
Number of subjects: 2993

Group type: COMPARATOR
Intervention: Pembrolizumab 2 mg/kg every 3 weeks (Q3W)
Number of subjects: 2993

Group type: COMPARATOR
Intervention: Pembrolizumab 10 mg/kg every 2 weeks (Q2W)
Number of subjects: 2993
Study: 32305219

Group type: EXPERIMENTAL
Intervention: VA-ECMO for TAAD
Number of subjects: 62
Study: 32306096

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2 mg/0.05 mL monthly for three injections followed by every 8 weeks
Number of subjects: 20
Study: 32306273

Group type: EXPERIMENTAL
Intervention: Time interval > 57 days after NRCT
Number of subjects: 167

Group type: COMPARATOR
Intervention: Time intervals 0-42 days and 43-56 days after NRCT
Number of subjects: 167
Study: 32306296

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (EQW)
Number of subjects: 954

Group type: COMPARATOR
Intervention: Placebo/non-glucagon-like peptide-1 receptor agonist comparator (sitagliptin, metformin, pioglitazone, dapagliflozin, insulin)
Number of subjects: 954
Study: 32306413

Group type: EXPERIMENTAL
Intervention: Behavioral sleep interventions (BSIs)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Feeding near bedtime or during the night
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Co-sleeping
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Parental sleep knowledge
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sleep characteristics measured by actigraphy
Number of subjects: 40
Study: 32306809

Group type: EXPERIMENTAL
Intervention: Resistive reserve ratio (RRR)
Number of subjects: 1245

Group type: COMPARATOR
Intervention: Fractional flow reserve (FFR)
Number of subjects: 1245

Group type: COMPARATOR
Intervention: Coronary flow reserve (CFR)
Number of subjects: 1245
Study: 32306965

Group type: EXPERIMENTAL
Intervention: WHOQOL-BREF
Number of subjects: 254
Study: 32307017

Group type: EXPERIMENTAL
Intervention: Prostate SBRT (37.5Gy, 5 fractions of 7.5Gy) guided by prostate gold fiducial markers
Number of subjects: 8
Study: 32307193

Group type: EXPERIMENTAL
Intervention: 1-3 eggs/week
Number of subjects: 18914

Group type: EXPERIMENTAL
Intervention: 3-7 eggs/week
Number of subjects: 18914

Group type: EXPERIMENTAL
Intervention: 1-2 eggs/day
Number of subjects: 18914

Group type: EXPERIMENTAL
Intervention: ≥2 eggs/day
Number of subjects: 18914

Group type: EXPERIMENTAL
Intervention: Cholesterol from eggs
Number of subjects: 18914

Group type: EXPERIMENTAL
Intervention: Cholesterol from non-egg sources
Number of subjects: 18914

Group type: EXPERIMENTAL
Intervention: Substituting 50 g/d egg for dairy products
Number of subjects: 18914

Group type: EXPERIMENTAL
Intervention: Substituting 50 g/d egg for nuts/legumes
Number of subjects: 18914

Group type: EXPERIMENTAL
Intervention: Substituting 50 g/d egg for red meat
Number of subjects: 18914
Study: 32307279

Group type: EXPERIMENTAL
Intervention: Single dose inactivated hepatitis-A virus (HAV) vaccine
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Single dose live attenuated varicella zoster virus (VZV) vaccine
Number of subjects: 259

Group type: COMPARATOR
Intervention: Single dose VZV vaccine
Number of subjects: 259
Study: 32307443

Group type: EXPERIMENTAL
Intervention: FIT combined with Family History Questionnaire (FHQ)
Number of subjects: 5979

Group type: COMPARATOR
Intervention: FIT only
Number of subjects: 5979
Study: 32307533

Group type: EXPERIMENTAL
Intervention: Dawn simulation light
Number of subjects: 23
Study: 32307594

Group type: EXPERIMENTAL
Intervention: Visual analysis
Number of subjects: 0
Study: 32307692

Group type: EXPERIMENTAL
Intervention: OCD patients
Number of subjects: 21

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 21
Study: 32308367

Group type: EXPERIMENTAL
Intervention: Fimasartan
Number of subjects: 566
Study: 32308505

Group type: EXPERIMENTAL
Intervention: FTD/TPI (35 mg/m²)
Number of subjects: 15
Study: 32308680

Group type: EXPERIMENTAL
Intervention: Insulin administration
Number of subjects: 6
Study: 32308987

Group type: EXPERIMENTAL
Intervention: PBMT/sMF during training and detraining (PBMT/sMF + PBMT/sMF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PBMT/sMF during training and placebo during detraining (PBMT/sMF + Placebo)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo during training and PBMT/sMF during detraining (Placebo+PBMT/sMF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo during training and detraining (Placebo+Placebo)
Number of subjects: 60
Study: 32309284

Group type: EXPERIMENTAL
Intervention: Adaptive Servo-Ventilation
Number of subjects: 0
Study: 32309426

Group type: EXPERIMENTAL
Intervention: NAC+CHO (300 mL of oral carbohydrate administered 2 hours before surgery)
Number of subjects: 77

Group type: COMPARATOR
Intervention: NAC (two cycles of chemotherapy followed by surgery)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Non-NAC (surgery alone)
Number of subjects: 77
Study: 32309637

Group type: EXPERIMENTAL
Intervention: Buprenorphine (BUP)
Number of subjects: 0
Study: 32309673

Group type: EXPERIMENTAL
Intervention: Standard Oncology care plus Palliative Care (PC)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard Oncology care
Number of subjects: 97
Study: 32310027

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2240

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 2240
Study: 32310137

Group type: EXPERIMENTAL
Intervention: MacPLUS FS (McMaster Premium LiteratUre Service Federated Search)
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: MacPLUS FS
Number of subjects: 908
Study: 32310146

Group type: EXPERIMENTAL
Intervention: AGE-ON tablet training program
Number of subjects: 32
Study: 32310294

Group type: EXPERIMENTAL
Intervention: Golimumab treatment
Number of subjects: 53
Study: 32310699

Group type: EXPERIMENTAL
Intervention: Morphine treatment with metoclopramide coadministration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine treatment without metoclopramide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no morphine treatment)
Number of subjects: 0
Study: 32310851

Group type: EXPERIMENTAL
Intervention: Predilation
Number of subjects: 17084

Group type: COMPARATOR
Intervention: Post-dilation
Number of subjects: 17084

Group type: COMPARATOR
Intervention: Moderate/severe CAC presence
Number of subjects: 17084
Study: 32311022

Group type: EXPERIMENTAL
Intervention: Preventive health checks with attributes: assess, advice, agree, assist, arrange
Number of subjects: 148
Study: 32311037

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 43

Group type: COMPARATOR
Intervention: Bariatric surgery
Number of subjects: 43

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 43
Study: 32311926

Group type: EXPERIMENTAL
Intervention: Healthy Diet (HD) - increase fruit and vegetable intake to 5 servings per day (equivalent to 500g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthy Diet plus Physical Activity (HD-PA) - same dietary intervention as HD plus engage in moderate-to-vigorous physical activities for at least 150 minutes per week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthy Diet (HD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthy Diet plus Physical Activity (HD-PA)
Number of subjects: 0
Study: 32311940

Group type: EXPERIMENTAL
Intervention: Active tACS intervention (77.5-Hz, 15-mA, 40-minute sessions for 4 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham tACS (placebo control)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Active tACS intervention
Number of subjects: 70
Study: 32312243

Group type: EXPERIMENTAL
Intervention: Connected behavioral condition
Number of subjects: 148

Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 148
Study: 32312249

Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (ISB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no regional block)
Number of subjects: 50
Study: 32312299

Group type: EXPERIMENTAL
Intervention: Appropriate transfusion strategy
Number of subjects: 177
Study: 32312783

Group type: EXPERIMENTAL
Intervention: Piperaquine
Number of subjects: 1000
Study: 32312893

Group type: EXPERIMENTAL
Intervention: Sunitinib (multi-kinase inhibitor)
Number of subjects: 13
Study: 32312891

Group type: EXPERIMENTAL
Intervention: Capivasertib monotherapy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Capivasertib in combination with Fulvestrant
Number of subjects: 63
Study: 32312974

Group type: EXPERIMENTAL
Intervention: Hepatic saturated fatty acids (SFA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mono- and polyunsaturated fatty acids
Number of subjects: 0
Study: 32313451

Group type: EXPERIMENTAL
Intervention: Latiglutenase (900 mg)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Latiglutenase
Number of subjects: 398
Study: 32313553

Group type: EXPERIMENTAL
Intervention: Ready-to-drink SPMC oral solution
Number of subjects: 0
Study: 32313731

Group type: EXPERIMENTAL
Intervention: Heat shock protein peptide complex-96 (HSPPC-96) vaccine
Number of subjects: 0
Study: 32314262

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of gastric content before anesthesia induction
Number of subjects: 138
Study: 32314268

Group type: EXPERIMENTAL
Intervention: Copanlisib (0.2-0.8 mg/kg intravenously) intermittently or weekly; Refametinib (30-50 mg twice daily orally) continuously or 4 days on/3 days off.
Number of subjects: 64
Study: 32314956

Group type: EXPERIMENTAL
Intervention: Task engagement with multimodal network analyses integrating functional and molecular neuroimaging.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased cognitive load above initial task engagement.
Number of subjects: 0
Study: 32314972

Group type: EXPERIMENTAL
Intervention: New algorithm based on the Quantra system
Number of subjects: 20

Group type: COMPARATOR
Intervention: Existing algorithm based on the ROTEM/Multiplate system
Number of subjects: 20
Study: 32314973

Group type: EXPERIMENTAL
Intervention: Delayed Auditory Feedback (DAF) + real transcranial direct current stimulation (tDCS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Delayed Auditory Feedback (DAF) + sham transcranial direct current stimulation (tDCS)
Number of subjects: 30
Study: 32314974

Group type: EXPERIMENTAL
Intervention: The Box 2.0 intervention consisting of seven home measurement devices and a video consultation 2 weeks after discharge.
Number of subjects: 730

Group type: COMPARATOR
Intervention: Standard cardiac care for 3 months.
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: The Box 2.0 intervention.
Number of subjects: 730
Study: 32315306

Group type: EXPERIMENTAL
Intervention: Breast milk components analysis using correlation, PCA, and graphical discovery analysis
Number of subjects: 156
Study: 32315373

Group type: EXPERIMENTAL
Intervention: EQ-5D-3L score at 1 week post-trauma
Number of subjects: 4883

Group type: EXPERIMENTAL
Intervention: HUI2 score at 1 week post-trauma
Number of subjects: 4883

Group type: EXPERIMENTAL
Intervention: HUI3 score at 1 week post-trauma
Number of subjects: 4883

Group type: EXPERIMENTAL
Intervention: EQ-5D-3L score at 24 months post-trauma
Number of subjects: 4883

Group type: EXPERIMENTAL
Intervention: HUI2 score at 24 months post-trauma
Number of subjects: 4883

Group type: EXPERIMENTAL
Intervention: HUI3 score at 24 months post-trauma
Number of subjects: 4883

Group type: EXPERIMENTAL
Intervention: IES score at 1 week post-trauma
Number of subjects: 4883

Group type: EXPERIMENTAL
Intervention: HADSA score at 1 week post-trauma
Number of subjects: 4883

Group type: EXPERIMENTAL
Intervention: HADSD score at 1 week post-trauma
Number of subjects: 4883

Group type: EXPERIMENTAL
Intervention: IES score at 24 months post-trauma
Number of subjects: 4883

Group type: EXPERIMENTAL
Intervention: HADSA score at 24 months post-trauma
Number of subjects: 4883

Group type: EXPERIMENTAL
Intervention: HADSD score at 24 months post-trauma
Number of subjects: 4883
Study: 32315434

Group type: EXPERIMENTAL
Intervention: Laser interstitial thermal therapy (LITT) using Robotic NeuroBlate System
Number of subjects: 223
Study: 32316080

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (28-mg, 56-mg, or 84-mg) plus new oral antidepressant (OAD) administered twice a week for 4 weeks, followed by weekly or every-other-week for responders during a 48-week optimization/maintenance phase.
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray plus new OAD
Number of subjects: 802
Study: 32316799

Group type: EXPERIMENTAL
Intervention: High-altitude acclimatization
Number of subjects: 0
Study: 32316976

Group type: EXPERIMENTAL
Intervention: SGRQ-I
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: K-BILD
Number of subjects: 150
Study: 32316977

Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy with customized forces
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (trained without assistance)
Number of subjects: 11